Lipoprotein(a) Management Simplified
Lipoprotein(a) Management Simplified
Sources: Medscape (Oct , 2026) | National Lipid Association (NLA)
• Measure Lp(a) once in every adult.
• High: ≥125 nmol/L (≥50 mg/dL) → ASCVD risk enhancer; intensify LDL-C and overall risk-factor control.
• Statins: may slightly ↑ Lp(a), but remain essential.
• PCSK9 inhibitors: ↓ Lp(a) ~20–30%.
• Niacin: ↓ Lp(a) ~20–30%, but not recommended—no CV outcome benefit and more adverse effects.
• Pelacarsen: ↓ Lp(a) ~80%, but did not significantly reduce MACE.
• Bottom line: Lowering Lp(a) does not necessarily mean better CV outcomes; treat the patient’s overall ASCVD risk, not the number alone.
Lipoprotein(a) Management Simplified: The National Lipid Association Lipid Simplified Series